Cutaneous Oncology News

Rescue and recovery workers who responded to the World Trade Center site after 9/11 will experience a greater cancer burden over the next 20 years than a demographically similar population, according to research published in JAMA Oncology.

Married patients with melanoma appeared more likely to present with early-stage disease than divorced, widowed or never-married patients, according to findings published in JAMA Dermatology.

Obesity appeared associated with improved survival among men with metastatic melanoma who underwent treatment with targeted therapy or immunotherapy, according to results of a pooled analysis.

Single-agent therapy with anti-PD-1 inhibitors induced response rates of 70% within a cohort of patients with metastatic desmoplastic melanoma.

The 95% increase in Merkel cell carcinoma incidence during a 13-year period at the start of this century appeared largely attributable to an aging population, according to study results.

NEW YORK — Combination therapy with BRAF and MEK inhibitors can confer long-term survival for patients with low-burden metastatic melanoma and should be a preferred treatment option, according to a presenter at HemOnc Today New York.

Clinicians should counsel children, their parents and young adults on the use of sun protective behaviors for the prevention of skin cancer, according to a final recommendation statement from the U.S. Preventive Services Task Force.

There was significant discrepancy between patient-reported full-body skin exams, physician reports of these exams, and documentation of the exams in patient charts, according to study findings presented at the American Academy of Dermatology annual meeting.

A high percentage of young firefighters in Florida developed skin cancer, suggesting the potential for elevated risk in this population, according to a research letter published in JAMA Dermatology.

NEW YORK — The pool of patients eligible to receive immunotherapy likely should include many individuals who were excluded from early immunotherapy trials, according to a presenter at HemOnc Today New York.